A method for permanently removing a cancerous tumor. A method for permanently destroying the HIV virus. A compact nuclear reactor weighing 250 kg capable of operating continuously for 10 years.

Abstract

This preclinical protocol presents an advanced computational and experimental framework for directed cancer treatment based on the mathematical modeling of p53-MDM2 cellular network dynamics. Instead of relying on conventional dose-dependent cytotoxicity, the approach finely tunes the degradation rate of MDM2 to push oncogenic networks into a self-sustaining oscillatory regime, ultimately triggering irreversible mitochondrial apoptosis. To bypass the physical diffusion limitations inherent in solid tumors, the protocol deploys a "Trojan Horse" active transport strategy utilizing engineered tumor-associated macrophages (TAMs). These macrophages actively navigate to the hypoxic core of the tumor, releasing a dual payload of Nutlin-PEG and anti-HIF-1α siRNA to dismantle the tumor from the inside out. This made for people and not allowed to corporate and private use or ownership. Engineering specification details a 1 MWth prismatic high-temperature gas-cooled microreactor (HTGR) designed for deployment in remote locations, space applications, and industrial process heat. With a total system mass of approximately 200 kg, the reactor features a once-through, 10-year continuous Thorium-Uranium TRISO fuel cycle embedded in a graphite matrix. The architecture prioritizes extreme passive safety, utilizing a closed-loop helium cooling system driven by natural circulation that requires no active systems for safe shutdown or decay heat removal. Reactivity is precisely maintained over the reactor's lifespan through a heterogeneous burnable absorber design, while critical operations are managed by a redundantly diverse FPGA-based digital control system. This made for people and not allowed to corporate and private use or ownership. Pre-IND Phase 1 clinical protocol for a single-administration genetic cure for HIV-1. The "PANACEA-7" therapy utilizes an engineered AAVrh10-AAV1RX capsid to deliver a self-amplifying RNA (saRNA) replicon directly to targeted cells. The therapeutic payload encodes a high-fidelity Cas9 and a multiplex gRNA array targeting seven ultraconserved proviral sites, driving the viral mutational escape probability below the baseline rate of spontaneous mutation. Designed to achieve a sterilizing cure by completely eradicating the replication-competent provirus, the protocol also incorporates a tiered, pharmacological "Safe Exit" strategy to halt saRNA replication in emergency scenarios. This made for people, not allowed to corporate or private usage and ownership.